HRP20050390A2 - Substituted benzoxazinones and uses thereof - Google Patents

Substituted benzoxazinones and uses thereof

Info

Publication number
HRP20050390A2
HRP20050390A2 HR20050390A HRP20050390A HRP20050390A2 HR P20050390 A2 HRP20050390 A2 HR P20050390A2 HR 20050390 A HR20050390 A HR 20050390A HR P20050390 A HRP20050390 A HR P20050390A HR P20050390 A2 HRP20050390 A2 HR P20050390A2
Authority
HR
Croatia
Prior art keywords
substituted benzoxazinones
formula
benzoxazinones
substituted
methods
Prior art date
Application number
HR20050390A
Other languages
English (en)
Croatian (hr)
Inventor
Maag Hans
Sui Meng
Zhao Shu-Hai
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20050390A2 publication Critical patent/HRP20050390A2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HR20050390A 2002-11-08 2005-05-02 Substituted benzoxazinones and uses thereof HRP20050390A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42494602P 2002-11-08 2002-11-08
PCT/EP2003/012278 WO2004041792A1 (en) 2002-11-08 2003-11-04 Substituted benzoxazinones and uses thereof

Publications (1)

Publication Number Publication Date
HRP20050390A2 true HRP20050390A2 (en) 2006-12-31

Family

ID=32312902

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050390A HRP20050390A2 (en) 2002-11-08 2005-05-02 Substituted benzoxazinones and uses thereof

Country Status (28)

Country Link
US (1) US7141562B2 (es)
EP (1) EP1562918B1 (es)
JP (1) JP4401297B2 (es)
KR (1) KR100683361B1 (es)
CN (1) CN100390157C (es)
AR (1) AR042002A1 (es)
AT (1) ATE384054T1 (es)
AU (1) AU2003293653B2 (es)
BR (1) BR0315302A (es)
CA (1) CA2505334A1 (es)
DE (1) DE60318733T2 (es)
DK (1) DK1562918T3 (es)
ES (1) ES2298609T3 (es)
GT (1) GT200300241A (es)
HR (1) HRP20050390A2 (es)
IL (1) IL168343A (es)
MX (1) MXPA05004758A (es)
MY (1) MY136824A (es)
NO (1) NO20052074L (es)
NZ (1) NZ539508A (es)
PA (1) PA8587501A1 (es)
PE (1) PE20040828A1 (es)
PL (1) PL377770A1 (es)
PT (1) PT1562918E (es)
RU (1) RU2328490C2 (es)
TW (1) TWI285639B (es)
WO (1) WO2004041792A1 (es)
ZA (1) ZA200503248B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
WO2005012254A1 (en) 2003-07-22 2005-02-10 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
JP4527730B2 (ja) * 2003-12-09 2010-08-18 エフ.ホフマン−ラ ロシュ アーゲー ベンゾオキサジン誘導体及びその使用
ES2359725T3 (es) * 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
JP2009501184A (ja) 2005-07-13 2009-01-15 エフ.ホフマン−ラ ロシュ アーゲー 5−ht6、5−ht24としてのベンゾイミダゾール誘導体
EP1954689A4 (en) * 2005-09-15 2009-09-02 Korea Res Inst Chem Tech SUBSTITUTED 1H-QUINOLINE-2,4-DIONES N, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
CA2658959A1 (en) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
MX2018000465A (es) 2015-07-15 2018-09-17 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa.
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения
LT3649124T (lt) * 2017-08-07 2021-06-10 Suven Life Sciences Limited Fluorpiperidino junginiai kaip grynieji 5-ht6 receptorių antagonistai
CN111559990B (zh) * 2020-05-29 2021-03-09 四川大学华西医院 一种小分子噁噻嗪类衍生物及其应用
CN112047898A (zh) * 2020-10-14 2020-12-08 兰州大学 一种苯并[c][1,2]噁嗪骨架类新化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81975T1 (de) 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
AU605304B2 (en) * 1987-06-22 1991-01-10 Nihon Tokushu Nayaku Seizo K.K. Benzo-fused cyclic compounds
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
DE69736704T2 (de) 1996-03-29 2007-09-13 Duphar International Research B.V. Piperazin- und piperidin- derivate
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
RU2246494C2 (ru) * 1999-08-23 2005-02-20 Солвей Фармасьютикалс Б.В. Новые фенилпиперазины
AU2001236606A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa
WO2001072725A1 (en) 2000-03-24 2001-10-04 Cor Therapeutics, Inc. BICYCLIC SULFONYL AMINO INHIBITORS OF FACTOR Xa
DE10031391A1 (de) 2000-07-03 2002-02-07 Knoll Ag Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
DE60127434T2 (de) * 2000-10-26 2007-11-29 Smithkline Beecham P.L.C., Brentford Benzoxazinonderivative, deren herstellung und verwendung
KR100608417B1 (ko) * 2001-08-10 2006-08-02 에프. 호프만-라 로슈 아게 5-ht6 수용체 친화성을 갖는 아릴설포닐 유도체
RS51042B (sr) * 2002-05-13 2010-10-31 F. Hoffmann-La Roche Ag. Derivati benzoksazina kao 5-ht6 modulatori i njihove primene

Also Published As

Publication number Publication date
PL377770A1 (pl) 2006-02-20
GT200300241A (es) 2004-06-03
MY136824A (en) 2008-11-28
PE20040828A1 (es) 2004-11-25
JP4401297B2 (ja) 2010-01-20
US20040092512A1 (en) 2004-05-13
JP2006514615A (ja) 2006-05-11
ATE384054T1 (de) 2008-02-15
IL168343A (en) 2010-05-31
MXPA05004758A (es) 2005-08-02
DK1562918T3 (da) 2008-05-05
CN100390157C (zh) 2008-05-28
PT1562918E (pt) 2008-03-12
AU2003293653A1 (en) 2004-06-07
RU2005117965A (ru) 2006-01-27
ES2298609T3 (es) 2008-05-16
DE60318733T2 (de) 2009-01-15
CA2505334A1 (en) 2004-05-21
AR042002A1 (es) 2005-06-08
RU2328490C2 (ru) 2008-07-10
ZA200503248B (en) 2006-02-22
PA8587501A1 (es) 2004-05-26
EP1562918A1 (en) 2005-08-17
NZ539508A (en) 2007-05-31
US7141562B2 (en) 2006-11-28
TW200418846A (en) 2004-10-01
EP1562918B1 (en) 2008-01-16
NO20052074L (no) 2005-06-01
DE60318733D1 (de) 2008-03-06
TWI285639B (en) 2007-08-21
CN1723205A (zh) 2006-01-18
KR100683361B1 (ko) 2007-02-15
WO2004041792A1 (en) 2004-05-21
KR20050072479A (ko) 2005-07-11
AU2003293653B2 (en) 2009-05-14
BR0315302A (pt) 2005-08-23

Similar Documents

Publication Publication Date Title
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
HRP20050775A2 (en) Quinolinone/benzoxazinone derivatives and uses thereof
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
ATE338461T1 (de) Pyrazolpyrimidinfungizide
BRPI0508966A (pt) composto, composição farmacêutica, e, uso de um composto
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
SE0202133D0 (sv) Novel compounds
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
EP1674452A4 (en) NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
SE0403171D0 (sv) New compounds
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
UY27980A1 (es) Indoles 2,7-sustituidos
BRPI0416873A (pt) derivados de benzoxazina e usos dos mesmos
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
RS50905B (sr) Derivati benzopirana supstituisani sa sekundarnim aminima uključujući tetrazol, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
ATE504583T1 (de) 4-imidazolin-2-onverbindungen
TWI263639B (en) Novel tetrazole derivative
UY26251A1 (es) Forma cristalina iii de la n- (4-(5- dimetilaminonaftalen-1- sulfonilamino) fenil) -3 - hidroxi-2, 2- dimetilpropionamida
UY28068A1 (es) Benzoxazinonas sustituidas y usos de las mismas

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20101029

Year of fee payment: 8

OBST Application withdrawn